Drugs / CKD-333
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04478097 | Jul → Nov 2020 | cardiovascular disorder | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
| Phase 1 | NCT04019743 | Jul → Aug 2019 | hyperlipidemia, hypertensive disorder | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT03849287 | Feb → Mar 2019 | hyperlipidemia, hypertensive disorder | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
| Phase 1 | NCT03659149 | Aug → Oct 2018 | hyperlipidemia, hypertensive disorder | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CKD-333 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03659149 ↗ |
| Route | Oral | “single oral administration under fasting condition” NCT04019743 ↗ |